Randomized, Placebo Controlled Blinded Study to Assess the Efficacy of Valsartan to Prevent Left Ventricle Remodeling in Patients With Dual Chamber Pacemaker
Latest Information Update: 14 Apr 2023
At a glance
- Drugs Valsartan (Primary)
- Indications Heart failure
- Focus Pharmacodynamics
- 10 Apr 2023 Status changed from active, no longer recruiting to discontinued.
- 01 Sep 2020 Results presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
- 01 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Feb 2019.